Brief: Monte Rosa Therapeutics Q4 Operating Expenses USD 47.643 Million
20/03/2025 11:00
Mar 20 (Reuters) - Monte Rosa Therapeutics Q4 pretax profit USD 15.601 million. Q4 net income USD 13.437 million Q4 operating income USD 13.004 million
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million